1. Academic Validation
  2. PRP19 Enhances Esophageal Squamous Cell Carcinoma Progression by Reprogramming SREBF1-Dependent Fatty Acid Metabolism

PRP19 Enhances Esophageal Squamous Cell Carcinoma Progression by Reprogramming SREBF1-Dependent Fatty Acid Metabolism

  • Cancer Res. 2023 Feb 15;83(4):521-537. doi: 10.1158/0008-5472.CAN-22-2156.
Guang-Cong Zhang # 1 Xiang-Nan Yu # 1 Hong-Ying Guo 1 Jia-Lei Sun 1 Zhi-Yong Liu 1 Ji-Min Zhu 1 Tao-Tao Liu 1 Ling Dong 1 Xi-Zhong Shen 1 2 3 Jie Yin 1
Affiliations

Affiliations

  • 1 Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai, China.
  • 2 Shanghai Institute of Liver disease, Shanghai, China.
  • 3 Key Laboratory of Medical Molecular Virology, Shanghai Medical College of Fudan University, Shanghai, China.
  • # Contributed equally.
Abstract

Lipid metabolism reprogramming is a recognized hallmark of Cancer cells. Identification of the underlying regulators of metabolic reprogramming in esophageal squamous cell carcinoma (ESCC) could uncover potential therapeutic targets to improve treatment. Here, we demonstrated that pre-mRNA processing factor 19 (PRP19) mediates reprogramming of lipid metabolism in ESCC. Expression of PRP19 was significantly upregulated in multiple ESCC cohorts and was correlated with poor clinical prognosis. PRP19 promoted ESCC proliferation in vitro and in vivo. Upregulation of PRP19 enhanced fatty acid synthesis through sterol regulatory element-binding protein 1 (SREBF1), a major transcription factor of lipid synthase. Moreover, PRP19 enhanced the stability of SREBF1 mRNA in an N6-methyladenosine-dependent manner. Overall, this study shows that PRP19-mediated fatty acid metabolism is crucial for ESCC progression. Targeting PRP19 is a potential therapeutic approach to reverse metabolic reprogramming in patients with ESCC.

Significance: Upregulation of pre-mRNA processing factor 19 (PRP19) contributes to esophageal squamous cell carcinoma progression by reprogramming SREBF1-dependent fatty acid metabolism, identifying PRP19 as a potential prognostic biomarker and therapeutic target.

Figures
Products